FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2790081845> ?p ?o ?g. }

• W2790081845 endingPage "49" @default.
• W2790081845 startingPage "42" @default.
• W2790081845 abstract "Aim. To estimate ibrutinib efficacy in the treatment of early CLL relapses and in patients with > 2 lines of preceding therapy. Analysis of treatment results in patients with del(17p) and monitoring of minimal residual disease (MRD) and ibrutinib safety profile. Materials & Methods. The analysis included the results of ibrutinib treatment in 31 patients with CLL. Twenty eight patients were treated by bendamustine and fludarabine containing regimens. The median prior treatment lines were 2 (range 1-10). The indications for the treatment initiation were the first early relapse in 51 % of cases (n = 16) and a relapse after 2 and more lines of therapy in 49 % of cases (n = 15). Ibrutinib was administered in mono- (n = 15) and combined therapy (n = 14) as well as in the R-BAC scheme (n = 2). Using FISH analysis del(17p) was found in 9 patients (34 %). Results. Within the median follow up of 18 months (range 7-42+) the overall survival (OS) rate was reported to be 87 %, and the progression-free survival (PFS) rate was 77 %. The maximum MRD after a year of ibrutinib treatment was observed in case of combination with immunochemother-apy (e.g., R-BAC). Within the period of 18 months OS rate was 100 %, in the patient group with early relapses and 66 % in the group with a relapse after 2 and more therapy lines (p = 0.02). Within the same examination period PFS was significantly higher (94 %) in the patient group with early relapses compared to the previously treated patients (60 %) (p = 0.034). The most common adverse events were grade 1-2 purpura (30 %), grade 1-2 diarrhea (10 %), atrial fibrillation paroxysms (10 %) and arterial hypertension (10 %). Severe infectious complications registered in 6 % (n = 3) patients were successfully solved in the course of combined antibacterial and antimycotic treatment. Conclusion. Ibrutinib was shown to be effective drug for treatment of relapsed CLL. The OS and PFS values were more favourable in patients with early relapses compared to the patients with relapses after > 2 lines of therapy prior to ibrutinib treatment. The maximum elimination of the tumor clone was observed after combined ibrutinib/immunochemotherapy treatment. The tolerance of ibrutinib was reported to be satisfactory with acceptable toxicity profile. No mortality due to infection complications was observed." @default.
• W2790081845 created "2018-03-29" @default.
• W2790081845 creator A5019403155 @default.
• W2790081845 creator A5024887955 @default.
• W2790081845 creator A5074129685 @default.
• W2790081845 creator A5082835558 @default.
• W2790081845 date "2018-01-01" @default.
• W2790081845 modified "2023-09-27" @default.
• W2790081845 title "Ibrutinib in the Treatment of Relapsed Chronic Lymphocytic Leukemia" @default.
• W2790081845 cites W1493658394 @default.
• W2790081845 cites W1976678201 @default.
• W2790081845 cites W2009009231 @default.
• W2790081845 cites W2011572687 @default.
• W2790081845 cites W2029903885 @default.
• W2790081845 cites W2103857518 @default.
• W2790081845 cites W2108206643 @default.
• W2790081845 cites W2112473520 @default.
• W2790081845 cites W2126849604 @default.
• W2790081845 cites W2150487985 @default.
• W2790081845 cites W2233614027 @default.
• W2790081845 cites W2295348655 @default.
• W2790081845 cites W2337485820 @default.
• W2790081845 cites W2507725926 @default.
• W2790081845 cites W2515639723 @default.
• W2790081845 cites W2519500141 @default.
• W2790081845 cites W2586663048 @default.
• W2790081845 cites W2741300627 @default.
• W2790081845 cites W2980141827 @default.
• W2790081845 cites W4235474157 @default.
• W2790081845 doi "https://doi.org/10.21320/2500-2139-2018-11-1-42-49" @default.
• W2790081845 hasPublicationYear "2018" @default.
• W2790081845 type Work @default.
• W2790081845 sameAs 2790081845 @default.
• W2790081845 citedByCount "1" @default.
• W2790081845 countsByYear W27900818452021 @default.
• W2790081845 crossrefType "journal-article" @default.
• W2790081845 hasAuthorship W2790081845A5019403155 @default.
• W2790081845 hasAuthorship W2790081845A5024887955 @default.
• W2790081845 hasAuthorship W2790081845A5074129685 @default.
• W2790081845 hasAuthorship W2790081845A5082835558 @default.
• W2790081845 hasBestOaLocation W27900818451 @default.
• W2790081845 hasConcept C126322002 @default.
• W2790081845 hasConcept C141071460 @default.
• W2790081845 hasConcept C143998085 @default.
• W2790081845 hasConcept C2776694085 @default.
• W2790081845 hasConcept C2776755627 @default.
• W2790081845 hasConcept C2777938653 @default.
• W2790081845 hasConcept C2778461978 @default.
• W2790081845 hasConcept C2779263901 @default.
• W2790081845 hasConcept C2779878957 @default.
• W2790081845 hasConcept C2781442060 @default.
• W2790081845 hasConcept C71924100 @default.
• W2790081845 hasConceptScore W2790081845C126322002 @default.
• W2790081845 hasConceptScore W2790081845C141071460 @default.
• W2790081845 hasConceptScore W2790081845C143998085 @default.
• W2790081845 hasConceptScore W2790081845C2776694085 @default.
• W2790081845 hasConceptScore W2790081845C2776755627 @default.
• W2790081845 hasConceptScore W2790081845C2777938653 @default.
• W2790081845 hasConceptScore W2790081845C2778461978 @default.
• W2790081845 hasConceptScore W2790081845C2779263901 @default.
• W2790081845 hasConceptScore W2790081845C2779878957 @default.
• W2790081845 hasConceptScore W2790081845C2781442060 @default.
• W2790081845 hasConceptScore W2790081845C71924100 @default.
• W2790081845 hasIssue "1" @default.
• W2790081845 hasLocation W27900818451 @default.
• W2790081845 hasLocation W27900818452 @default.
• W2790081845 hasOpenAccess W2790081845 @default.
• W2790081845 hasPrimaryLocation W27900818451 @default.
• W2790081845 hasRelatedWork W1550739321 @default.
• W2790081845 hasRelatedWork W2100707039 @default.
• W2790081845 hasRelatedWork W2177663541 @default.
• W2790081845 hasRelatedWork W2284975440 @default.
• W2790081845 hasRelatedWork W2294347960 @default.
• W2790081845 hasRelatedWork W2316985579 @default.
• W2790081845 hasRelatedWork W2558110451 @default.
• W2790081845 hasRelatedWork W2607778160 @default.
• W2790081845 hasRelatedWork W2794302045 @default.
• W2790081845 hasRelatedWork W4200500254 @default.
• W2790081845 hasVolume "11" @default.
• W2790081845 isParatext "false" @default.
• W2790081845 isRetracted "false" @default.
• W2790081845 magId "2790081845" @default.
• W2790081845 workType "article" @default.